RGNX - REGENXBIO Inc Stock Price, Fair Value and News

16.07USD+0.03 (+0.19%)Market Closed

Market Summary

USD16.07+0.03

Market Closed

0.19%

RGNX Alerts

1 major insider sales recently.

RGNX Stock Price

View Fullscreen

RGNX RSI Chart

RGNX Valuation

Market Cap

714.0M

Price/Earnings (Trailing)

-2.71

Price/Sales (Trailing)

7.91

EV/EBITDA

-2.84

Price/Free Cashflow

-3.13

RGNX Price/Sales (Trailing)

RGNX Profitability

EBT Margin

-292.15%

Return on Equity

-84.52%

Return on Assets

-45.91%

Free Cashflow Yield

-31.99%

RGNX Fundamentals

RGNX Revenue

Revenue (TTM)

90.2M

Rev. Growth (Yr)

-29.13%

Rev. Growth (Qtr)

-23.18%

RGNX Earnings

Earnings (TTM)

-263.5M

Earnings Growth (Yr)

-4.93%

Earnings Growth (Qtr)

-1.65%

Breaking Down RGNX Revenue

Last 7 days

-0.2%

Last 30 days

-25.8%

Last 90 days

26.3%

Trailing 12 Months

-12.7%

How does RGNX drawdown profile look like?

RGNX Financial Health

Current Ratio

2.57

RGNX Investor Care

Shares Dilution (1Y)

2.22%

Diluted EPS (TTM)

-6.02

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	109.6M	97.0M	99.4M	90.2M
2022	473.7M	484.3M	480.0M	112.7M
2021	155.8M	161.3M	93.1M	470.3M
2020	52.0M	60.7M	144.9M	154.6M
2019	172.7M	126.9M	81.1M	35.2M
2018	142.3M	175.8M	179.8M	218.5M
2017	4.7M	8.8M	10.0M	10.4M
2016	7.3M	8.3M	7.3M	4.6M
2015	3.8M	3.6M	4.3M	7.6M
2014	6.1M	6.1M	6.1M	6.1M
2013	0	0	0	6.1M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of REGENXBIO Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 15, 2024	mills kenneth t.	acquired	56,400	3.76	15,000	president and ceo
Apr 15, 2024	mills kenneth t.	sold	-272,871	18.1914	-15,000	president and ceo
Mar 19, 2024	vasista vittal	acquired	75,354	3.76	20,041	chief financial officer
Mar 14, 2024	mills kenneth t.	acquired	112,800	3.76	30,000	president and ceo
Mar 14, 2024	mills kenneth t.	sold	-655,884	21.8628	-30,000	president and ceo
Mar 05, 2024	pakola steve	acquired	286,536	22.25	12,878	chief medical officer
Mar 05, 2024	pakola steve	sold	-365,220	28.36	-12,878	chief medical officer
Feb 14, 2024	mills kenneth t.	acquired	56,400	3.76	15,000	president and ceo
Feb 14, 2024	mills kenneth t.	sold	-251,349	16.7566	-15,000	president and ceo
Jan 16, 2024	mills kenneth t.	acquired	169,200	3.76	45,000	president and ceo

Which funds bought or sold RGNX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 24, 2024	DekaBank Deutsche Girozentrale	unchanged	-	268,000	1,644,000	-%
Apr 24, 2024	Assenagon Asset Management S.A.	added	113	2,880,820	4,795,760	0.01%
Apr 23, 2024	Global Retirement Partners, LLC	added	1,704	8,029	8,365	-%
Apr 23, 2024	Louisiana State Employees Retirement System	reduced	-0.99	58,810	421,400	0.01%
Apr 23, 2024	FIFTH THIRD BANCORP	added	617	11,456	13,000	-%
Apr 23, 2024	WASHINGTON TRUST Co	unchanged	-	583	3,940	-%
Apr 23, 2024	AMALGAMATED BANK	reduced	-15.07	-1,000	261,000	-%
Apr 22, 2024	Raymond James Financial Services Advisors, Inc.	reduced	-13.08	23,973	1,206,930	-%
Apr 22, 2024	MetLife Investment Management, LLC	unchanged	-	33,268	400,770	-%
Apr 22, 2024	RAYMOND JAMES & ASSOCIATES	added	9.13	254,850	1,161,990	-%

Are Funds Buying or Selling RGNX?

Are funds buying RGNX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own RGNX

No. of Funds

RGNX Alerts

1 major insider sales recently.

Unveiling REGENXBIO Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	redmile group, llc	8.6%	3,760,690	SC 13G/A
Feb 13, 2024	vanguard group inc	10.09%	4,440,838	SC 13G/A
Feb 05, 2024	gic private ltd	2.37%	1,042,011	SC 13G/A
Jan 25, 2024	state street corp	5.98%	2,631,220	SC 13G/A
Jan 25, 2024	jpmorgan chase & co	8.9%	3,932,521	SC 13G/A
Jan 25, 2024	jpmorgan chase & co	8.9%	3,932,521	SC 13G/A
Jan 19, 2024	blackrock inc.	18.7%	8,207,548	SC 13G/A
Nov 17, 2023	redmile group, llc	9.6%	4,238,312	SC 13G
May 10, 2023	vanguard group inc	10.04%	4,362,426	SC 13G/A
Apr 07, 2023	gic private ltd	5.1%	2,198,514	SC 13G

Recent SEC filings of REGENXBIO Inc

View All Filings

Date Filed	Form Type	Document
Apr 17, 2024	4	Insider Trading
Apr 04, 2024	ARS	ARS
Apr 04, 2024	DEF 14A	DEF 14A
Apr 04, 2024	DEFA14A	DEFA14A
Mar 21, 2024	4	Insider Trading
Mar 18, 2024	4	Insider Trading
Mar 11, 2024	8-K	Current Report
Mar 08, 2024	424B5	Prospectus Filed
Mar 07, 2024	4	Insider Trading
Mar 07, 2024	FWP	Prospectus Filed

Peers (Alternatives to REGENXBIO Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	40.6B	6.8B	-1.15%	-18.78%	-8.61	5.92	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.1B	1.8B	-5.46%	-27.26%	-41.1	9.9	76.23%	61.08%
BMRN	15.5B	2.4B	-6.36%	-11.66%	92.47	6.41	15.42%	18.43%
INCY	11.5B	3.7B	-9.50%	-30.40%	19.23	3.11	8.87%	75.42%
MID-CAP
APLS	5.8B	396.6M	-18.85%	-43.46%	-10.92	14.56	425.83%	18.94%
BBIO	4.3B	-	-18.25%	70.26%	-6.55	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-6.76%	2.03%	-14.16	12.52	440.80%	-27.84%
ARWR	2.7B	240.7M	-21.52%	-38.49%	-9.12	12.18	-1.03%	-92.09%
ACAD	2.7B	726.4M	-8.32%	-19.69%	-43.85	3.7	40.45%	71.62%
SMALL-CAP
CPRX	1.7B	398.2M	-6.79%	-8.36%	24.23	4.35	85.90%	-14.05%
NVAX	552.8M	983.7M	-16.14%	-47.54%	-1.01	0.56	-50.36%	17.16%
CRBP	351.2M	881.7K	-7.41%	335.24%	-7.87	466.16	-77.61%	-5.33%
INO	236.5M	4.9M	-18.26%	4.12%	-1.75	48.6	-54.97%	51.71%
IBIO	5.9M	2.1M	47.83%	55.96%	-0.22	2.14	-13.45%	66.37%

REGENXBIO Inc News

Latest updates

REGENXBIO Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	-23.2%	22,213,000	28,914,000	19,977,000	19,138,000	31,345,000	26,512,000	32,649,000	22,218,000	398,655,000	30,773,000	22,035,000	18,884,000	21,445,000	98,912,000	16,566,000	17,644,000	11,768,000	14,700,000	7,881,000	24,329,000	40,777,000
Costs and Expenses	-8.3%	86,116,000	93,874,000	93,085,000	85,295,000	89,116,000	97,557,000	95,182,000	93,745,000	85,059,000	88,121,000	74,261,000	62,926,000	75,096,000	84,961,000	58,399,000	55,344,000	52,092,000	50,596,000	44,753,000	36,790,000	38,327,000
S&GA Expenses	-17.3%	19,079,000	23,083,000	23,698,000	22,634,000	21,210,000	20,921,000	20,832,000	22,318,000	22,040,000	21,030,000	18,425,000	17,838,000	17,571,000	15,859,000	15,554,000	14,833,000	14,450,000	12,402,000	13,405,000	11,558,000	11,144,000
R&D Expenses	-4.3%	55,681,000	58,183,000	59,886,000	58,516,000	62,505,000	63,313,000	61,008,000	55,627,000	47,978,000	47,855,000	45,882,000	39,722,000	47,180,000	43,968,000	38,111,000	37,035,000	33,807,000	35,692,000	29,483,000	25,203,000	24,329,000
EBITDA Margin	-12.8%	-2.65	-2.35	-2.51	-2.15	-2.17	0.26	0.29	0.32	0.38	-2.11	-0.81	-0.69	-0.63	-	-	-	-	-	-	-	-
Interest Expenses	-16.1%	1,363,000	1,624,000	1,120,000	2,755,000	4,310,000	5,954,000	6,860,000	6,130,000	6,500,000	6,709,000	6,366,000	6,702,000	-	-	-	-	-	-	-	-	-
Income Taxes	-	-	-	-	-	-43,000	-	-	-41,000	13,403,000	-	-	4,000	5,743,000	-3,000	-500,000	-	-2,461,000	-165,000	-129,000	70,000	1,621,000
Earnings Before Taxes	-1.9%	-63,041,000	-61,868,000	-72,061,000	-66,676,000	-59,978,000	-75,484,000	-68,179,000	-76,764,000	307,426,000	-58,405,000	-57,639,000	-50,135,000	-40,498,000	8,788,000	-34,262,000	-40,038,000	-28,855,000	-34,749,000	-1,586,000	-32,298,000	5,927,000
EBT Margin	-11.4%	-2.92	-2.62	-2.83	-2.47	-2.49	0.18	0.21	0.24	0.30	-2.22	-0.86	-0.75	-0.69	-	-	-	-	-	-	-	-
Net Income	-1.7%	-62,889,000	-61,868,000	-72,061,000	-66,676,000	-59,935,000	-75,484,000	-68,179,000	-76,723,000	294,023,000	-58,405,000	-57,639,000	-50,139,000	-46,241,000	8,791,000	-33,762,000	-40,038,000	-26,464,000	-34,584,000	-1,457,000	-32,228,000	4,306,000
Net Income Margin	-11.4%	-2.92	-2.62	-2.83	-2.47	-2.49	0.15	0.19	0.21	0.27	-2.28	-0.90	-0.78	-0.72	-	-	-	-	-	-	-	-
Free Cashflow	17.6%	-41,886,000	-50,846,000	-49,899,000	-85,736,000	-44,842,000	-55,506,000	-70,986,000	-66,878,000	326,883,000	-61,201,000	-55,914,000	-75,068,000	26,579,000	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-9.4%	574	634	682	748	833	884	953	1,025	1,114	800	836	879	708	541	450	464	498	509	529	519	544
Current Assets	-8.4%	335	366	379	389	416	437	465	447	519	410	437	499	531	387	329	338	345	360	359	304	338
Cash Equivalents	-34.9%	35.00	53.00	69.00	70.00	97.00	119	121	192	345	228	257	291	338	93.00	94.00	69.00	70.00	80.00	55.00	56.00	76.00
Net PPE	-2.5%	132	136	139	142	142	141	139	135	132	122	107	89.00	56.00	39.00	33.00	30.00	29.00	28.00	27.00	23.00	29.00
Liabilities	-3.1%	262	271	277	283	317	320	323	336	350	339	329	325	330	126	52.00	44.00	48.00	41.00	35.00	32.00	35.00
Current Liabilities	2.3%	130	127	118	112	130	124	115	120	130	107	92.00	84.00	81.00	64.00	40.00	32.00	34.00	31.00	25.00	21.00	22.00
Shareholder's Equity	-14.1%	312	363	406	465	516	564	631	690	764	461	507	555	378	416	398	420	450	468	495	487	509
Retained Earnings	-9.8%	-705	-642	-580	-508	-441	-381	-306	-237	-161	-455	-396	-339	-289	-242	-251	-217	-177	-151	-116	-115	-83.02
Additional Paid-In Capital	0.8%	1,021	1,013	996	985	973	964	951	940	928	918	905	895	667	658	649	639	628	619	611	602	593
Shares Outstanding	0.1%	44.00	44.00	44.00	43.00	43.00	43.00	43.00	43.00	42.00	43.00	43.00	43.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	805	-	-	-	985	-	-	-	1,310	-	-	-	978	-	-	-	1,356	-	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	17.5%	-40,760	-49,407	-47,322	-80,918	-39,372	-50,456	-61,749	-55,911	341,497	-42,503	-36,072	-44,047	39,468	-36,460	-21,496	-35,573	-25,506	-29,153	-23,749	-29,297	-4,140
Share Based Compensation	-18.4%	8,338	10,219	10,504	11,206	9,408	10,245	10,335	10,800	9,162	9,734	9,992	9,920	7,581	8,035	8,316	8,017	6,875	7,162	7,099	5,718	4,886
Cashflow From Investing	-12.1%	33,974	38,657	55,218	63,094	26,700	53,043	-1,081	-90,591	-216,359	16,101	7,799	-214,183	11,570	33,998	44,482	32,709	14,154	52,272	21,672	5,461	-67,182
Cashflow From Financing	-148.9%	-11,962	-4,805	-9,162	-9,037	-8,920	-5,417	-7,669	-6,834	-7,616	-2,283	-6,137	211,286	194,168	1,460	1,825	2,761	1,549	1,333	1,367	4,127	5,288

RGNX Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenues
Revenues	$ 90,242	$ 112,724	$ 470,347
Operating Expenses
Cost of revenues	37,213	54,545	51,833
Research and development	232,266	242,453	181,437
General and administrative	88,494	85,281	79,333
Credit losses (recoveries)	0	0	(2,569)
Other operating expenses (income)	397	(6,679)	333
Total operating expenses	358,370	375,600	310,367
Income (loss) from operations	(268,128)	(262,876)	159,980
Other Income (Expense)
Interest income from licensing	25	342	719
Investment income	11,319	5,383	6,825
Interest expense	(6,862)	(23,254)	(26,277)
Total other income (expense)	4,482	(17,529)	(18,733)
Income (loss) before income taxes	(263,646)	(280,405)	141,247
Income Tax Benefit (Expense)	152	84	(13,407)
Net income (loss)	(263,494)	(280,321)	127,840
Other Comprehensive Income (Loss)
Unrealized gain (loss) on available-for-sale securities, net	10,972	(12,832)	(2,209)
Total other comprehensive income (loss)	10,972	(12,832)	(2,209)
Comprehensive income (loss)	$ (252,522)	$ (293,153)	$ 125,631
Earnings Per Share [Abstract]
Basic	$ (6.02)	$ (6.5)	$ 3.01
Diluted	$ (6.02)	$ (6.5)	$ 2.91
Weighted-average common shares outstanding:
Basic	43,734	43,152	42,438
Diluted	43,734	43,152	43,913
License and royalty [Member]
Revenues
Revenues	$ 90,242	$ 112,724	$ 470,347

RGNX Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets
Cash and cash equivalents	$ 34,522	$ 96,952
Marketable securities	240,736	267,690
Accounts receivable (net of allowance of $4,587 as of December 31, 2023)	24,790	28,082
Prepaid expenses	14,520	13,900
Other current assets	20,403	9,352
Total current assets	334,971	415,976
Marketable securities	38,871	200,560
Accounts receivable (net of allowance of $4,152 as of December 31, 2022)	701	1,504
Property and equipment, net	132,103	141,685
Operating lease right-of-use assets	60,487	65,116
Restricted cash	2,030	2,030
Other assets	4,807	6,397
Total assets	573,970	833,268
Current liabilities
Accounts payable	22,786	27,213
Accrued expenses and other current liabilities	49,703	46,794
Deferred revenue	148	1,829
Operating lease liabilities	7,068	5,997
Liability related to sale of future royalties	50,567	48,601
Total current liabilities	130,272	130,434
Operating lease liabilities	82,222	88,802
Liability related to sale of future royalties	43,485	89,005
Other liabilities	6,249	8,832
Total liabilities	262,228	317,073
Commitments and contingencies (Note 8)
Stockholders’ equity
Preferred stock; $0.0001 par value; 10,000 shares authorized, no shares issued and outstanding at December 31, 2023 and 2022
Common stock; $0.0001 par value; 100,000 shares authorized at December 31, 2023 and 2022; 44,046 and 43,299 shares issued and outstanding at December 31, 2023 and 2022, respectively	4	4
Additional paid-in capital	1,021,214	973,145
Accumulated other comprehensive loss	(4,429)	(15,401)
Accumulated deficit	(705,047)	(441,553)
Total stockholders’ equity	311,742	516,195
Total liabilities and stockholders’ equity	$ 573,970	$ 833,268

About REGENXBIO Inc

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. In addition, it also develops RGX-121 for the treatment of mucopolysaccharidosis type II and is in Phase III clinical trial; RGX-111, which is in Phase I/II clinical trial for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. Further, the company also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop novel gene therapies. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.

CEO	Mr. Kenneth T. Mills
WEBSITE	regenxbio.com
INDUSTRY	Biotechnology
EMPLOYEES	401

REGENXBIO Inc Frequently Asked Questions

What is the ticker symbol for REGENXBIO Inc? What does RGNX stand for in stocks?

RGNX is the stock ticker symbol of REGENXBIO Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of REGENXBIO Inc (RGNX)?

As of Thu Apr 25 2024, market cap of REGENXBIO Inc is 713.95 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of RGNX stock?

You can check RGNX's fair value in chart for subscribers.

What is the fair value of RGNX stock?

You can check RGNX's fair value in chart for subscribers. The fair value of REGENXBIO Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of REGENXBIO Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for RGNX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is REGENXBIO Inc a good stock to buy?

The fair value guage provides a quick view whether RGNX is over valued or under valued. Whether REGENXBIO Inc is cheap or expensive depends on the assumptions which impact REGENXBIO Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for RGNX.

What is REGENXBIO Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Apr 25 2024, RGNX's PE ratio (Price to Earnings) is -2.71 and Price to Sales (PS) ratio is 7.91. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. RGNX PE ratio will change depending on the future growth rate expectations of investors.